For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | - | - | - | 0 |
| Research and development | 267,240 | 511,878 | 943,478 | 1,025,547 |
| General and administrative | 1,160,556 | 1,843,530 | 886,055 | 2,346,323 |
| Legal and professional | 789,026 | 432,827 | 437,409 | 538,536 |
| Total operating expenses | 2,216,822 | 2,788,235 | 2,266,942 | 3,910,406 |
| Net loss from operations | -2,216,822 | -2,788,235 | -2,266,942 | -3,910,406 |
| Interest expense-Related Party | - | 3,727.5* | 721 | 2,614 |
| Interest expense | 12,122 | 6,130* | 18,183 | 19,129 |
| Change in fair value of marketable securities | - | - | - | 0 |
| Gain on sale of marketable securities | - | - | - | 0 |
| Interest income | 209 | 239.5* | 486 | 81 |
| Change in fair value of derivative liabilities | 76,264 | -91,149 | 2,427 | 11,673 |
| Loss on settlement of convertible debt | - | - | - | 0 |
| Change in fair value of convertible notes | - | -60,433 | -64,369 | 213,930 |
| Gain on settlement of debt | - | 334,540* | - | - |
| Total other (expense) income | 64,351 | 173,340 | -80,360 | 203,941 |
| Net loss | -2,152,471 | -2,614,895 | -2,347,302 | -3,706,465 |
| Basic EPS | -0.43 | -1.596 | -1.05 | -3.29 |
| Diluted EPS | -0.43 | -1.596 | -1.05 | -3.29 |
| Basic Average Shares | 5,031,569 | 1,637,926* | 2,233,650 | 1,126,054 |
| Diluted Average Shares | 5,031,569 | 1,637,926* | 2,233,650 | 1,126,054 |
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)